Levonorgestrel

This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W7SIA7YZW, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)- but generally known as levonorgestrel, which bears US NIH Compound Identifier 13109. European Medicines Agency schedules Levonorgestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08483MIG. The term LEVONORGESTREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules levonorgestrel in its Anatomical Therapeutic Chemical (ATC) Classification. LEVONORGESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levonorgestrel under HS 29372300 and SITC 54153. As of Q4 2014, LEVONORGESTREL remains the US FDA Preferred Term for this commodity. Levonorgestrel bears US NLM identifiers UMLS ID C1145675 and NCI Concept Code C47585. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)CC)C#C.